Johnson & Johnson (NYSE:JNJ) updated its FY 2018 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $8.13-8.18 for the period, compared to the Thomson Reuters consensus estimate of $8.15. The company issued revenue guidance of $81-81.4 billion, compared to the consensus revenue estimate of $81.21 billion.Johnson & Johnson also updated its FY18 guidance to $8.13-8.18 EPS.

A number of equities analysts have issued reports on the company. Wells Fargo & Co reiterated an outperform rating and set a $160.00 target price on shares of Johnson & Johnson in a report on Friday, September 14th. Credit Suisse Group set a $149.00 target price on Johnson & Johnson and gave the stock a buy rating in a report on Sunday. ValuEngine upgraded Johnson & Johnson from a sell rating to a hold rating in a report on Saturday, July 28th. Goldman Sachs Group upgraded Johnson & Johnson from a sell rating to a neutral rating in a report on Thursday, July 12th. Finally, Jefferies Financial Group set a $145.00 target price on Johnson & Johnson and gave the stock a buy rating in a report on Sunday, July 15th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the stock. The company currently has an average rating of Hold and an average target price of $143.80.

Johnson & Johnson stock opened at $136.56 on Wednesday. Johnson & Johnson has a one year low of $118.62 and a one year high of $148.32. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.65 and a quick ratio of 1.33. The stock has a market cap of $370.70 billion, a PE ratio of 18.71, a price-to-earnings-growth ratio of 2.19 and a beta of 0.70.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 16th. The company reported $2.05 EPS for the quarter, topping the Zacks’ consensus estimate of $2.03 by $0.02. Johnson & Johnson had a net margin of 1.70% and a return on equity of 32.79%. The company had revenue of $20.35 billion during the quarter, compared to the consensus estimate of $20.05 billion. During the same period in the prior year, the business posted $1.90 EPS. The company’s quarterly revenue was up 3.6% on a year-over-year basis. On average, sell-side analysts expect that Johnson & Johnson will post 8.14 earnings per share for the current fiscal year.

In other news, CAO Ronald A. Kapusta sold 7,899 shares of the stock in a transaction dated Friday, September 7th. The shares were sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the completion of the transaction, the chief accounting officer now directly owns 25,725 shares in the company, valued at approximately $3,528,955.50. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, COO Michael E. Sneed sold 29,000 shares of the stock in a transaction dated Monday, August 27th. The stock was sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the transaction, the chief operating officer now owns 59,124 shares of the company’s stock, valued at $7,969,915.20. The disclosure for this sale can be found here. Corporate insiders own 0.22% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. CSat Investment Advisory L.P. acquired a new stake in Johnson & Johnson in the 2nd quarter valued at about $107,000. Fort L.P. acquired a new stake in Johnson & Johnson in the 2nd quarter valued at about $120,000. Price Wealth Management Inc. lifted its stake in Johnson & Johnson by 39.5% in the 2nd quarter. Price Wealth Management Inc. now owns 1,988 shares of the company’s stock valued at $242,000 after purchasing an additional 563 shares during the last quarter. Youngs Advisory Group Inc. acquired a new stake in Johnson & Johnson in the 2nd quarter valued at about $253,000. Finally, RPg Family Wealth Advisory LLC lifted its stake in Johnson & Johnson by 202.0% in the 2nd quarter. RPg Family Wealth Advisory LLC now owns 2,226 shares of the company’s stock valued at $270,000 after purchasing an additional 1,489 shares during the last quarter. Institutional investors own 66.67% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: How much money do you need to begin day trading?

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.